CYTOPHAGE TECHNOLOGIES LTD (CYTO.CA) Fundamental Analysis & Valuation

TSX-V:CYTO • CA2328211081

Current stock price

0.065 CAD
0 (0%)
Last:

This CYTO.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. CYTO.CA Profitability Analysis

1.1 Basic Checks

  • CYTO had negative earnings in the past year.
  • In the past year CYTO has reported a negative cash flow from operations.
CYTO.CA Yearly Net Income VS EBIT VS OCF VS FCFCYTO.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 -2M -4M -6M

1.2 Ratios

Industry RankSector Rank
ROA -143.59%
ROE -391.47%
ROIC N/A
ROA(3y)-114.73%
ROA(5y)N/A
ROE(3y)-539.45%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CYTO.CA Yearly ROA, ROE, ROICCYTO.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 -200 -400 -600 -800 -1K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for CYTO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CYTO.CA Yearly Profit, Operating, Gross MarginsCYTO.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. CYTO.CA Health Analysis

2.1 Basic Checks

  • CYTO has more shares outstanding than it did 1 year ago.
  • The debt/assets ratio for CYTO has been reduced compared to a year ago.
CYTO.CA Yearly Shares OutstandingCYTO.CA Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 10M 20M 30M 40M 50M
CYTO.CA Yearly Total Debt VS Total AssetsCYTO.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 1M 2M 3M 4M 5M

2.2 Solvency

  • CYTO has an Altman-Z score of -14.47. This is a bad value and indicates that CYTO is not financially healthy and even has some risk of bankruptcy.
  • A Debt/Equity ratio of 0.98 indicates that CYTO is somewhat dependend on debt financing.
Industry RankSector Rank
Debt/Equity 0.98
Debt/FCF N/A
Altman-Z -14.47
ROIC/WACCN/A
WACCN/A
CYTO.CA Yearly LT Debt VS Equity VS FCFCYTO.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 2M -2M 4M -4M -6M

2.3 Liquidity

  • CYTO has a Current Ratio of 0.66. This is a bad value and indicates that CYTO is not financially healthy enough and could expect problems in meeting its short term obligations.
  • CYTO has a Quick Ratio of 0.66. This is a bad value and indicates that CYTO is not financially healthy enough and could expect problems in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 0.66
Quick Ratio 0.66
CYTO.CA Yearly Current Assets VS Current LiabilitesCYTO.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 1M 2M 3M 4M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. CYTO.CA Growth Analysis

3.1 Past

  • CYTO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 71.14%, which is quite impressive.
EPS 1Y (TTM)71.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%16.83%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocksShow best growing peers

0

4. CYTO.CA Valuation Analysis

4.1 Price/Earnings Ratio

  • CYTO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CYTO.CA Price Earnings VS Forward Price EarningsCYTO.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CYTO.CA Per share dataCYTO.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.02 -0.04 -0.06

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CYTO.CA Dividend Analysis

5.1 Amount

  • No dividends for CYTO!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CYTO.CA Fundamentals: All Metrics, Ratios and Statistics

CYTOPHAGE TECHNOLOGIES LTD

TSX-V:CYTO (3/27/2026, 7:00:00 PM)

0.065

0 (0%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)N/A
Earnings (Next)N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners12.73%
Ins Owner ChangeN/A
Market Cap4.40M
Revenue(TTM)N/A
Net Income(TTM)-4.57M
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.77
P/tB 3.77
EV/EBITDA N/A
EPS(TTM)-0.08
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.05
FCFYN/A
OCF(TTM)-0.05
OCFYN/A
SpS0
BVpS0.02
TBVpS0.02
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -143.59%
ROE -391.47%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-114.73%
ROA(5y)N/A
ROE(3y)-539.45%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.98
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 16.06%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.66
Quick Ratio 0.66
Altman-Z -14.47
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)106.84%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)71.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%16.83%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y21.19%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-101.11%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-66.87%
OCF growth 3YN/A
OCF growth 5YN/A

CYTOPHAGE TECHNOLOGIES LTD / CYTO.CA Fundamental Analysis FAQ

What is the fundamental rating for CYTO stock?

ChartMill assigns a fundamental rating of 0 / 10 to CYTO.CA.


Can you provide the valuation status for CYTOPHAGE TECHNOLOGIES LTD?

ChartMill assigns a valuation rating of 0 / 10 to CYTOPHAGE TECHNOLOGIES LTD (CYTO.CA). This can be considered as Overvalued.


What is the profitability of CYTO stock?

CYTOPHAGE TECHNOLOGIES LTD (CYTO.CA) has a profitability rating of 0 / 10.


How financially healthy is CYTOPHAGE TECHNOLOGIES LTD?

The financial health rating of CYTOPHAGE TECHNOLOGIES LTD (CYTO.CA) is 1 / 10.